Phase I Clinical Trial of Tolerability and Pharmacokinetics of TQB3702 Tablets in Hematologic Tumor Subjects
Latest Information Update: 16 Nov 2022
At a glance
- Drugs TQB-3702 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 16 Nov 2022 New trial record